VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.

VIVUS' investigational pipeline includes:

  • Qnexa® for obesity, which recently completed phase 3 development.  Our NDA application was accepted by the FDA on Feb 26, 2009 with an action date of Oct 28, 2010.
  • Qnexa for diabetes currently in phase 2. Data from the phase 2 diabetes study was initially announced in December 2008.
  • Qnexa for obstructive sleep apnea currently in phase 2. Data from the phase 2 efficacy and safety study was announced in January 2010.
  • Avanafil, which is currently in phase 3 development for the treatment of erectile dysfunction (ED).
PDF Print E-mail  
© 2010 VIVUS Inc. All rights reserved.